Summary
Targeted delivery of superparamagnetic iron oxide nanoparticles (SPIONs) could facilitate their accumulation in metastatic cancer cells in peripheral tissues, lymph nodes and bones and enhance the sensitivity of magnetic resonance imaging (MRI). The specificities of luteinizing hormone releasing hormone (LHRH) and luteinizing hormone/chorionic gonadotropin (LH/CG)- bound SPIONs were tested in human breast cancer cells in vitro and were found to be dependent on the receptor expression of the target cells, the time of incubation and showed saturation kinetics. In incubations with MDA-MB-435S.luc cells, the highest iron accumulation was 452.6 pg Fe/cell with LHRH-SPIONs, 203.6 pg Fe/cell with β-CG-SPIONs and 51.3 pg Fe/cell with SPIONs. Incubations at 4 °C resulted in 1.1 pg Fe/cell. Co-incubation with the same ligands (βCG or LHRH) decreased the iron accumulation in each case. LHRH-SPIONs were poorly incorporated by macrophages. Tumors and metastatic cells from breast cancer xenografts were targeted in vivo in a nude mouse model. LHRH-SPION specifically accumulated in cells of human breast cancer xenografts. The amount of LHRH-SPION in the lungs was directly dependent on the number of metastatic cells and amounted to 77.8 pg Fe/metastastic cell. In contrast, unconjugated SPIONs accumulated in the liver, showed poor affinity to the tumor, and were not detectable in metastatic lesions in the lungs. LHRH-SPION accumulated in the cytosolic compartment of the target cells and formed clusters. LHRH-SPIONs did not accumulate in livers of normal mice. In conclusion, LHRH conjugated SPIONs may serve as a contrast agent for MR imaging in vivo and increase the sensitivity for the detection of metastases and disseminated cells in lymph nodes, bones and peripheral organs.
Similar content being viewed by others
Abbreviations
- LHRH:
-
luteinizing hormone releasing hormone
- CG:
-
chorionic gonadotropin
- βCG :
-
fragment of the beta chain of CG from amino acid 81–95
- MRI:
-
magnetic resonance imaging
- SPION:
-
superparamagnetic iron oxide nanoparticles
- CT:
-
computed tomography
- PET:
-
positron emission tomography
- CHO:
-
Chinese Hamster Ovary Cells
- PMA:
-
4α Porbol 12 myristate 13 acetate
- s.c.:
-
subcutanously
References
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ Cancer Statistics, 2005CA Cancer J Clin55:10–30, 2005
Braun S, Kentenich Ch, Janni W, Hepp F, Waal J de, Wilgeroth F, Sommer H, Pantel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patientsJ Clin Oncol18: 80–86, 2000
Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K Simultaneous immunohistochemical detection of tumor cells in lymph nodes, bone marrow aspirates in breast cancer and its correlation with other prognostic factorsJ Clin Oncol19: 960–971, 2001
Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, Rjosk D, Hepp F: Comparative analysis of micrometastasis to the bone marrow, lymph nodes of node-negative breast cancer patients receiving no adjuvant therapyJ Clin Oncol19: 1468–1475, 2001
Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, Brakenhoff R, Pantel K: Molecular signature associated with bone marrow micrometastasis in human breast cancerCancer Res 63:5679–5684, 2003
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G: Cytokeratin-positive cells in the bone marrow, survival of patients with stage I, II, or III breast cancerN Engl J Med342:525–533, 2000
Pantel K, Otte M: Occult micrometastasis: enrichment, identification, characterization of single disseminated tumor cellsSemin Cancer Biol11: 327–337, 2001
Pantel K, Cote RJ, Fodstadt O: Detection, clinical importance of micrometastatic diseaseJ Natl Cancer Inst91:1113–1124 1999
Pantel K, Mueller V, Auer M, Nusser N, Harbeck N, Braun S: Detection, clinical implications of early systemic tumor cell dissemination in breast cancerClin Cancer Res9:6326–6334, 2003
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinomaCell79:315–328, 1994
Kruger WH, Kroger N, Togel F, Renges H, Badbaran A, Hornung R, Jung R, Gutensohn K, Gieseking F, Janicke F, Zander AR: Disseminated breast cancer cells prior to, after high-dose therapyJ Hematother Stem Cell Res10:681–689, 2001
Diel IJ, Krempien B, Kaufmann M, Costa SD, Goerner R, von Fournier D, Bastert G: Ergebnisse von Beckenkammbiopsien von 475 Patientinnen mit primaerem und metastasiertem MammakarzinomTumor Diagn Ther13: 85–90, 1992
Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: Influence of organ environment on the growth selection and metastasis of human colon carcinoma cells in nude miceCancer Res48: 6863–6871, 1988
Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink Hmc, Powles TJ, Ford HT, Neville AM: Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigenBr J Cancer44: 85–90, 1981
Tschentscher P, Wagener C, Neumaier M: Sensitive, specific cytokeratin 18 reverse transcriptase-polymerase chain reaction that excludes amplification of processed pseudogenes from contaminating genomic DNAClin Chem43: 2244–2250, 1997
Robsen ME, (2004) Offit K. Breast MRI for women with hereditary cancer riskJAMA 292: 1368
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA: Related articles, links surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examinationJAMA 292(11): 1317–1325, 2004
Morris EA, Schwartz LH, Dershaw DD: MR imaging of the breast in patients with occult primary breast carcinoma Radiology205: 437–440, 1997
Schorn C, Fischer U: MRI of the breast in patients with metastatic disease of unknown primaryEur Radiol9: 470–473, 1999
Clement O, Siauwe N: Liver imaging with ferrumxodidesTop Magn Res Imaging9: 167–182, 1998
Wang YXJ, Hussain SM, Kresting GP: Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imagingEur Radiol11:2319–2331, 2001
Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L: Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imagingRadiology 175:489–493, 1990
Seneterre E, Weissleder R, Jaramillo D, Reimer P, Lee AS, Brady TJ, Wittenberg J: Bone marrow: ultrasmall superparamagnetic iron oxide for MR imagingRadiology179: 529–533, 1991
Pouliquen D, Lucet I, Chouly C, Perdrisot R, Le Jeune JJ, Jallet P: Related articles, links liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects Magn Reson Imaging11: 219–228, 1993
Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobas P. Lewis J: Superparamagnetic iron oxide: pharmacokinetics and toxicityAm J Roentgenol152:167–173, 1989
Bonnemain B, (1998) Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applicationsJ Drug Target 6: 167–174
Daldrup HE, Link TM, Blasius S, Strozyk A, Konemann S, Jurgens H, Rummeny EJ: Monitoring radiation induced changes in bone marrow histopathology with ultra small superparamagnetic iron oxide (USPIO) enhanced MRIJ Magn Reson Imaging 9: 643–652, 1999
Van de Berg BC, Lecouvert FE, Kanku JP, Jamart J, Van Beers BE, Maldague B, Malghem J: Ferrumoxides enhanced quantitative magnetic resonance imaging of the normal and abnormal bone marrow. Preliminary assessmentJ Magn Reson Imaging9: 322–328, 1999
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, Hulsbergen C, Rosette J, Weissleder R: Noninvasive detection of clinically occult lymph node metastases in prostate cancerNew Engl J Med348: 2491–2499, 2003
Mintorovich J, Shansi K, Eovist: injection, reovist injection, two liver specific contrast agents for MRI. Oncology Supp 3 14: 37–40, 2000
Foster-Gareau P, Heyn C, Alejski A, Rutt BK: Imaging single mammalian cells with a 1.5 T clinical MRI scannerMagn Reson Med49: 968–971, 2003
Hinds KA, Hill JM, Shapiro EM, Laukkanen MO, Silva AC, Combs CA, Varney T R, Balaban RS, Koretsky AP, Dunbar CE: Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cellsBlood102: 867–872, 2003
Hogemann D, Josephson L, Weissleder R, Basilion JP: Related articles, links improvement of MRI probes to allow efficient detection of gene expressionBioconjug Chem11:941–946, 2000
Choi H, Choi SR, Zhou R, Kung HF, Chen IW: Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted deliveryAcad Radiol11:996–1004, 2004
Zhang Y, Kohler N, Zhang M: Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptakeBiomaterials23:1553–1561, 2002
Lojun S, Bao S, Lei ZM, Rao CV: Presence of functional luteinizing hormone/chorionic gonadotropin receptors in human breast cell lines: implications supporting the premise that CG protects women against breast cancerBiol Reprod57:1202–1210, 1997
Chatzistamou L, Schally AV, Nagi A, Szepeshazi K, Halmos G: Effective treatment of metastatic MDA-MB-435 human estrogen independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone releasing hormone AN-207Clin Cancer Res6:4158–4168, 2000
Leuschner C, Enright F, Gawronska B, Hansel W: Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivoBreast Cancer Res Treat78: 17–27, 2003
Leuschner C, Hansel W: Targeting breast and prostate cancers through their hormone receptorsBiol Reprod73: 255–260, 2005
Morbeck DE, Roche PC, Keutmann HT, McCormick DJ: A receptor binding site identified in the region 81–95 of the beta-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG)Mol Cell Endocrinol97: 173–181, 1993
Kumar C, Leuschner C, Doomes EE, Henry L, Juban M, Hormes J: Efficacy of lytic peptide bound magnetite nanoparticles in destroying breast cancer cellsJ Nanosci Nanotechnol4:245–249, 2004
Rubio N, Espana L, Fernandez Y, Blanco J, Sierra A: Metastatic behaviour of human breast carcinomas overexpressing the Bcl-xl Gene: a role in dormancy and organospecificityLab Invest81: 725–734, 2001
Rubio N, Villacampa MM, Hilali NE, Blanco J: Metastatic burden in nude mice organs measured using prostate tumor PC-3 cells expressing the luciferase gene as a quantifiable tumor cell markerProstate 44:133–143, 2000
Moyle WR, Capmpbell RK, Myers RV, Bernard MP, Han Y, Wang X: Co-evolution of ligand-receptor pairsNature368: 251–255, 1994
Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C: Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10Invest Radiol39:56–63, 2004
Leuschner C, Enright FM, Melrose PA, Hansel W: Targeted destruction of androgen-sensitive and insensitive prostate cancer cells and xenografts through luteinizing hormone receptorsProstate46:116–125, 2001
Leuschner C, Enright F, Gawronska-Kozak B, Hansel W: Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptorsProstate 56:239–249, 2003
Chen DW, Liao MH: Preparation and characterization of YADH-bound magnetic nanoparticlesJ Mol Cat B:Enzym16: 283–291, 2002
Huang SH, Liao MH, Chen DH: Direct binding and characterization of lipase onto magnetic nanoparticlesBiotechnol Prog19: 1095–1100, 2003
Sonoda N, Katabuchi H, Tashire H, Ohba T, Nishimura R, Minegishi T, Okamura H: Expression of variant luteinizing hormone/chorionic gonadotropin receptors and degradation of chorionic gonadotropin in human chorionic villous macrophagesPlacenta26, 298–307, 2005
Zhou J, Leuschner C, Kumar C, Hormes FJ, Soboyejo W: Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastasesBiomaterials27: 2001–2008, 2006
Leuschner C, Kumar CSSR, Hansel W, Hormes J: Targeting breast cancer cells and their metastses through luteinizing hormone releasing hormone (LHRH) using magnetic nanoparticlesJ Biomed Nanotechnol2: 229–233, 2005
Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP: MRI detection of single particles for cellular imaging. Proc Natl Acad Sci USA101: 10901–10906, 2004
Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F: Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imagingMagn Reson Med 49:646–654, 2003
Moore A, Marecos E, Bogdanov A, Weissleder R: Tumoral distribution of long-circulating dextran coated iron oxide nanoparticles in a rodent modelRadiology214: 568–574, 2000
Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K: MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agentsMagn Reson Imaging22: 843–850, 2004
Berry CC, Charles S, Wells S, Da.by MJ, Curtis AS: The influence of transferring stabilized magnetic nanoparticles on human dermal fibroblasts in culture. Int J Pharm 269, 211-, 2004; Int J Pharmaceutics, 2004
Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L: A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineationCancer Res 63: 8122–8125, 2003
Bergey EJ, Levy L, Wang X, Krebs LJ, Lal M, Kim KS, Pakatchi S, Liebow C, Prasad PN: DC magnetic filed induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro Biomed Microdev4: 293–299, 2002
Josephson L, Tung CH, Moore A, Weissleder R: Highefficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugatesBioconjugate Chem10: 186–191, 1999
Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz JD Jr, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD: Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticlesJ Immunol Methods256:89–105, 2001
Chouly C, Pouliquen D, Lucet J, Jeune JJ, Jallet P: Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistributionJ Microencapsul 13:245–255, 1996
Roser M, Fischer D, Kissel T: Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats Eur J Pharm Biopharm 46:255–263, 1998
Shieh DB, Chen FY, Su CH, Yeh CS, Wu MT, Wu YN, Tsai CY, Wu DH, Chen DH, Chou CH: Aequeous dispersions of magnetite nanoparticles with NH+ surfaces for magnetic manipulations of biomolecules and MRI contrast agentsBiomaterials26: 7183–7191, 2005
Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P: Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolismMagn Reson Imaging9:275–283, 1991
Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr: Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology. 162:211–216, 1987
Tiefenauer LX, Tschirky A, Kuhne G, Andres RY: In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRIMagn Reson Imaging14:391–402, 1996
Pineaud F, King D: Bioactivation and cell targeting of semiconductore CdSeJ Am Chem Soc126: 6115–6123, 2004
Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J: Superparamagnetic iron oxide: pharmacokinetics and toxicityAJR Am J Roentgenol152:167–173, 1989
Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R: Human transferrin receptor gene as a marker gene for MR imagingRadiology221:244–250, 2001
Zhou JK, Meng J, Thieraux C, Leuschner C, Kumar C, Hormes J, Soboyejo WO: LHRH-Functionalized Magnetite Nanoparticles for Breast Cancer Detection and Treatment, American Academy for Nanomedicine, Baltimore MD, 2005
Acknowledgements
Supported by PBRC/LSU, Nutrition and Chronic Disease Section, pilot project award: Detection of disseminated cells and micrometastases by ligand conjugated superparamagnetic iron oxid nanoparticles. PI: Carola Leuschner.
Financial support from the Center of Advanced Microstructures and Devices is gratefully acknowledged. The authors thank Dr Yuri Lvov and his team from the Louisiana Tech University, Ruston for providing the measurements for the zeta potentials.
Part of this study was published as a communication (Carola Leuschner, Challa SSR Kumar, Josef Hormes, William Hansel. Targeting breast cancer cells and their metastases through luteinizing hormone releasing hormone (LHRH) receptors using magnetic nanoparticles. Journal of Biomedical Nanotechnology Vol 2, 229–233, 2005.)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leuschner, C., Kumar, C.S., Hansel, W. et al. LHRH-conjugated Magnetic Iron Oxide Nanoparticles for Detection of Breast Cancer Metastases. Breast Cancer Res Treat 99, 163–176 (2006). https://doi.org/10.1007/s10549-006-9199-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9199-7